It has also been shown that treatment with a neutralizing anti-IL-17A antibody can reduce the angiogenesis of the tumor as well as reduce the inflammatory response, thereby reducing the growth of lung cancer progression (24, 26). The gene discussed is IL17A; the disease is lung cancer.